A typical Antipsychotic Induced Weight Gain: Pathophysiology and Management

References

• Flegal KM, Carroll MD, Kuczmarski RJ, Johnson CL: Overweight and obesity in the United States: prevalence and trends, 1960-1994. In J Obes Relat Metab Disord 1998; 22(1):39–47.
   PubMed Web of Science ®Google Scholar
• National Institutes of Health. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the evidence report. Obesity Res 1998; 6\(suppl 2):50s–63s.
   Google Scholar
• Mokdad AH, Bowman BA, Ford ES, Vinicor F, Marks JS, Koplan JP. The continuing epidemic of obesity and diabetes in the United States. JAMA 2001; 286:1195–1200.
   PubMed Web of Science ®Google Scholar
• Gordon HL, Law A, Hohman KE. The problem of over-weight in hospitalized psychotic patients. Psychiatry Quarterly 1960; 34:69–82.
   Google Scholar
• Allison DB, Fontaine KR, Moonseong H. The distribu-tion of body mass index among individuals with and without schizophrenia. J Clin Psych 1999; 60:215–220.
   Google Scholar
• Gopalaswamy AK, Morgan R. Too many chronic mentally disabled patients are too fat. Acta Psychitr Scand 1985; 72:254–258.
   PubMed Web of Science ®Google Scholar
• Tsuang MT, Perkins K, Simpson JC. Physical diseases in schizophrenia and affective disorder. J Clin Psych 1983; 44(2):42–46.
   Google Scholar
• Ananth J, Venkatesh, R, Burgoyne K, Gunatilake S: Atypical antipsychotic drug use and diabetes. Psycho-somatics and Psychotherapy 2002; 71:244–254.
   PubMed Web of Science ®Google Scholar
• Bernstein JG: Induction of obesity by psychotropic drugs. Annals of the New York Academy of Sciences 1987; 499:203–215.
   PubMedGoogle Scholar
• Baptista T. Bodyweight gain induced by antipsychotic drugs: Mechanisms and management. Acta Psych Scand 1999; 100:3–16.
   PubMed Web of Science ®Google Scholar
• Klett CJ, Caffey EM Jr. Weight changes during treat-ment with phenothiazine derivatives. J Neuropsych 1960; 2:102–108.
   Google Scholar
• Holden JM, Holden UP. Weight changes with schizo-phrenic psychosis and psychotropic drug therapy. Psy-chosomatics 1970; 11(6):551–561.
   Google Scholar
• Branchey MH, Lee JH, Amin R, Simpson GM. High-and low-potency neuroleptics in elderly psychiatric patients. JAMA 1978; 239(18):1860–1862.
   Google Scholar
• Silverstone T, Smith G, Goodall E. Prevalence of obe-sity in patients receiving depot antipsychotics. Br J Psych 1988; 153:214–217.
   Google Scholar
• Dufresne RL, Valentino D, Kass DJ. Thioridazine improves affective symptoms in schizophrenic patients. Psychopharm Bull 1993; 29(2):249–255.
   Google Scholar
• Doss FW. The effect of antipsychotic drugs on body weight: a retrospective review. J Clin Psych 1979; 40:528–530.
   Web of Science ®Google Scholar
• Bernstein JG: Psychotropic drug induced weight gain: mechanisms and management. Clin Neuropharm 1988; 11\(suppl 1):s194–s206.
   Google Scholar
• Rockwell WJ, Ellinwood EH Jr., Trader DW: Psychotro-pic drugs promoting weight gain: health risks and treat-ment implications. S Med Jour 1983; 76(11):1407–1412.
   Google Scholar
• Brady, KT. Weight gain associated with psychotropic drugs. S Med Jour 1989; 82:611–617.
   PubMed Web of Science ®Google Scholar
• Bhavnani SM, Levin GM. Antipsychotic agents: A survey of the prevalence, severity and burden of side effects. Int Clin Psychopharm 1996; 11(1):1–12.
   Google Scholar
• Allison DB, Casey DE. Antipsychotic-induced weight gain: a review of the literature. J Clin Psych 2001; 62\(suppl 7):22–31.
   Google Scholar
• Casey DE. The relationship of pharmacology to side effects. J Clin Psych 1997; 58\(suppl 10):55–62.
   Google Scholar
• Lieberman JA, Kane JM, Johns CA. Clozapine: guide-lines for clinical management. J Clin Psych 1989; 50:329–338.
   Google Scholar
• Naber D, Hippius H. The European experience with clozapine. Hosp Comm Psych 1990; 41:886–890.
   PubMedGoogle Scholar
• Povlsen UJ, Noring U, Fog R, Gerlach J. Tolerability and therapeutic effect of clozapine: a retrospective investigation of 216 patients treated with clozapine for up to 12 years. Acta Psych Scand 1985; 71:176–185.
   PubMed Web of Science ®Google Scholar
• Hummer M, Kemmler WC, Kurz M, Kurzthaler I, Oberbauer H, Fleischhacker WW. Weight gain induced by clozapine. Eur Neuropsychopharm 1995; 5(4): 437–440.
   PubMed Web of Science ®Google Scholar
• Wirshing DA, Wirshing WC, Kysar L, Berisford MA, Goldstein D, Pashdag J, Mintz J, Marder SR. Novel antipsychotics: Comparison of weight gain liabilities. J Clin Psych 1999; 60(6):358–363.
   Google Scholar
• Tran PV, Hamilton SH, Kuntz AJ. Double-blind com-parison of olanzapine versus risperidone in the treat-ment of schizophrenia and other psychotic disorders. J Clin Psychopharm 1997; 17:407–418.
   Google Scholar
• Tohen M, Zarate CA. Antipsychotic agents and bipolar disorder. J Clin Psych 1998; 59\(suppl 1):38–48.
   Google Scholar
• Guille C, Sachs GS, Ghaemisn. A naturalistic compari-son of clozapine, risperidone, and olanzapine in the treatment of bipolar disorder. J Clin Psych 2000; 61(9):638–642.
   Google Scholar
• Frankenburg FR, Zanarini MC, Kando J, Centorrino F. Clozapine and body mass change. Biol Psych 1998; 43:520–524.
   PubMedGoogle Scholar
• George TP, Sernyak MJ, Ziedonis DM, Woods SW. Effects of clozapine on smoking in chronic schizo-phrenic outpatients. J Clin Psych 1995; 156:344–346.
   Google Scholar
• Grunberg NE:Smoking cessation and weight gain. N Engl J Med. 1991; 324:768–769.
   PubMedGoogle Scholar
• Bustillo JR, Buchanan RW, Irish D, et al. Differential effect of clozapine on weight: a controlled study. Am J Psychiatry. 1996; 153:817–819.
   PubMed Web of Science ®Google Scholar
• Jalenques I, Tauveron I, Albuisson E, et al. [Weight gain and clozapinel (Fre) Encephale 1996; 22(spec no 3): 77–79.
   Google Scholar
• Leadbetter R, Shutty M, Pavalonis D, Vieweg V, Higgins P, Downs M. Clozapine induced weight gain: prevalence and clinical relevance. Am J Psych 1992; 149:68–72.
   PubMed Web of Science ®Google Scholar
• Bai YM, Lin CC, Chen JY, Lin CY: Weight gain among patients on clozapine. Psych Ser 1999; 50(5): 704–705.
   Google Scholar
• Lamberti JS, Bellnier T, Schwarzkopf SB. Weight gain among schizophrenic patients treated with clozapine. Am J Psychiatry 1992; 149:689–690.
   PubMed Web of Science ®Google Scholar
• Umbricht DS, Pollack S, Kane JM. Clozapine and weight gain. J Clin Psychiatry 1994; 55(suppl B):157–160.
   Google Scholar
• Zhang ZJ, Yao ZJ, Zhang XB, et al: No association of antipyschotic agent-induced weight gain with a DA receptor gene polymorphism and therapeutic response. Acta Pharmacol Sin 2003; 24:235–240.
   Google Scholar
• Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psych 1994; 151(6):825–835.
   PubMed Web of Science ®Google Scholar
• Csernansky JG, Mahmoud R, Brenner R. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. New Eng J Med 2002; 348:16–22.
   Google Scholar
• Conley RR, Mahmoud R, and Risperidone Study Group: A randomized double-blind study of risperidone and olanzapine in patients with schizophrenia and schizoaf-fective disorder. Am J Psychiatry 2001; 158: 765–774.
   PubMed Web of Science ®Google Scholar
• Peuskens JA. On behalf of Risperdione Study Group: Risperidone in the treatment of patients with chronic schizophrenia: a multinational multicenter double-blind parallel group study versus haloperidol. Br J Psych 1995; 166:712–726.
   PubMed Web of Science ®Google Scholar
• Hoyberg OJ, Fensbo C, Remvig J, Lingjaerde O, Sloth-Nielsen M, Slavesen I. Risperidone versus perphena-zine in the treatment of chronic schizophrenic patients with acute exacerbations. Ada Psychiatr Scand 1993; 88:395–402.
   Google Scholar
• Csernansky J, Okamoto A. Risperidone versus halo-peridol in the prevention of relapse in chronic schizo-phrenia and schizoaffective disorders: a long-term double blind comparison. Eur Neuropsychopharm 1999; 9\(suppl 5):s268p.
   Google Scholar
• Cohen S, Glazewski R, Khan S, Khan A. Weight gain with risperidone among patients with mental retard-ation: effect of calorie restriction. J Clin Psych 2001; 62:114–116.
   Google Scholar
• Arvanitis LA, Miller BG. Multiple fixed doses of "seroquel" (quetiapine) in patients with acute exacerba-tion of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group. Bio Psych 1997; 42(4): 233–246 .
   Google Scholar
• Peuskens JA. Comparison of quetiapine and chlorpro-mazine in the treatment of schizophrenia. Ada Psych Scand 1997; 96:265–273.
   PubMed Web of Science ®Google Scholar
• Small JG, Hirsch SR, Arvanitis LA. Quetiapine in patients with schizophrenia. Arch Gen Psych 1997; 54:549–557.
   PubMed Web of Science ®Google Scholar
• Tandon R, Harrigan E, Zorn S. Ziprasidone: a novel antipsychotic with unique pharmacology and therapeu-tic potential. J Serotonin Res 1997; 4:159–177.
   Google Scholar
• Daniel DG, Zimbroff DL, Potkin SG, Reeves KR, Harrigan EP, Lakshminarayanan M. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a six week placebo controlled trial. Neuropsychopharm 1999; 20(5):491–505.
   Google Scholar
• Keck P Jr., Buffenstein A, Ferguson J, Feighner J, Jaffe W, Harrigan EP, Morrissey MR. Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4 week placebo con-trolled trial. Psychopharm 1998; 140(2): 173–184.
   Google Scholar
• Weiden P, Simpson G, Kramer T: Switching from olanzapine to ziprasidone: clinical effects. Eur Neuro-psychopharm 1999; 9\(suppl 5):s264.
   Google Scholar
• Simpson G, Potkin S, Switch Study Group. Switching from risperidone to ziprasidone. Eur Neuropsycho-pharm 1999; 9\(suppl 5):s265.
   Google Scholar
• Arato MO, O'Connor R, Meltzer H. Ziprasidone inves-tigators Study Group. Ziprasidone: efficacy in the prevention of relapse and in the long-term treatment of negative symptoms of chronic schizophrenia. Eur Neuro-psychopharm 1997; 7\(suppl 2):5214.
   Google Scholar
• Beasley CM Jr, Tollefson GD, Tran PV. Safety of olan-zapine. J Clin Psych 1997; 58\(suppl 10):13–17.
   Google Scholar
• Zyprexa PDR: Physician's Desk Reference. Montvale, N.J., Med Econ 1999; 1641–1645.
   Google Scholar
• Sachs GS, Guille C. Weight gain associated with use of psychotropic medications. J Clin Psych 1999; 60\(suppl 21):16–19.
   Google Scholar
• Conley RR, Meltzer HY: Adverse events related to olanzapine. J Clin Psych 2000; 61\(suppl 8):26–29; discussion 30.
   Google Scholar
• Gupta, S, Droney T, Al-Samarrai S, Keller P, Frank B. Olanzapine induced weight gain. Ann Clin Psych 1999; 10:39.
   Google Scholar
• Robinson RG, McHugh PR, Folstein MF. Measurement of appetite disturbances in psychiatric disorders. J Psych Res 1975; 12:59–68.
   PubMed Web of Science ®Google Scholar
• Amdisen A. Drug produced obesity. Experiences with chlorpromazine, perphenazine, and clopenthixol. Dan Med Bull 1964; 11:182–189.
   PubMedGoogle Scholar
• Johnson DAW, Breen M: Weight changes with depot neuroleptic maintenance therapy. Ada Psych Scand 1979; 59:525–528.
   PubMedGoogle Scholar
• Umbricht DSG, Pollack S, Kane JM. Clozapine and weight gain. J Clin Psych 1994; 55(suppl B):157–160.
   Google Scholar
• Stanton JM. Weight gain associated with neuroleptic medication: a review. Schiz Bull 1995; 21:463–472.
   PubMedGoogle Scholar
• Kinon B, Basson B, Gilmore JA, Tollefson GD. Long-term olanzapine treatment: weight change and weight related health factors in schizophrenia. J Clin Psych 2001; 62:92–100.
   Google Scholar
• Henderson D, Cagliero E, Gray C, Nasrallah RA, Hayden DL, Schonfeld DA, Goff DC. Clozapine, diabetes mellitus, weight gain and lipid abnormalities: a five year naturalistic study. Am J Psych 2000; 57(6):975–981.
   Google Scholar
• Sahu A, Kalra SP. Neuropeptide regulation of feeding behavior: neuropeptide Y. Trends in Endocrinology and Metabolism 1993; 4:217–224.
   PubMed Web of Science ®Google Scholar
• Casey DE, Zorn SH. The pharmacology of weight gain with antipsychotics. J Clin Psych 2001; 62\(suppl 7):4–10.
   Google Scholar
• Yanovski JA, Yanovski SZ. Recent advances in basic obesity research. JAMA 1999; 282:1504–1506.
   PubMed Web of Science ®Google Scholar
• Thornton-Jones, Z, Neill JC, Reynolds GP. The atypical antipsychotic olanzapine enhances ingestive behavior in the rat: A preliminary study. J Psychopharmacology 2002; 16:35–37.
   Google Scholar
• Kaur G, Srinivas K, Kulkarni K: Studies on modulation of feeding behavior by atypical antipsychotics in female mice. Progress in Neuro-psychopharmacology & Biological Psychiatry 2002; 26:277–285.
   Google Scholar
• Baptista, T, Parada M, Hernadez L. Long term administra-tion of some antipsychotic drugs increases bodyweight and feeding in rats: are dopamine receptors involved? Pharmacol Biochem Behav 1987; 27:399–405.
   PubMedGoogle Scholar
• Baptista T, Reyes D, Hernandez L: Antipsychotic drugs and reproductive hormones: relationship to body weight regulation. Pharmacol Biochem Behav 1999; 62:409–417.
   Google Scholar
• Ellinwood VL, Miller D, Schultz SK, Wehring H, Arndt S. CYP2D6 polymorphisms and atypical antipsychotic weight gain. Psychiatric Genetics 2002; 12: 55–58.
   Google Scholar
• Dourish CT. Multiple serotonin receptors-opportun-ities for new treatments for obesity. Obesity Res 1995;
   Google Scholar
• Jackson HC, Heal DJ. A comparison of 5HT releasing agents and reuptake inhibitors as antiobesity drugs. Neurosci News 1999; 2(6):12–21.
   Google Scholar
• Stromborn U, Krotkiewski M, Blennow, J, Mansson JE, Ekman R, Bjorntorp P. The concentration of monoamine metabolites and neuropeptides in the cerebrospinal fluid of obese women with different body fat distribution. Int J Obesity Related Metabolic Disorders 1996; 20:361–368.
   Google Scholar
• Davis R, Faulds D. Dexfenfluramine. An updated review of its therapeutic use in the management of obesity. Drugs 1996; 52:696–724.
   Google Scholar
• McGuirk J, Muscat R, Wilner P. Effects of chronically administered fluoxetine and fenfluramine on food intake, body weight and the behavioral satiety sequence. Psychopharmacology 1992; 106:401–407.
   Google Scholar
• Lightowler S, Wood M, Brown T, Glen A, Blackburn T, Tulloch I, Kennett G. An investigation of the mechanism responsible for fluoxetine induced hypophagia in rats. Eur J Pharmacology 1996; 296:137–143.
   Google Scholar
• Victor IR. Olanzapine: a novel atypical neuroleptic agent. Lancet 1997; 394:1264–1265.
   Google Scholar
• Terry P, Katz JL. A comparison of the effects of DI receptor antagonist SCH 23390 and SCH 39166 on suppression of feeding behavior by the D1 agonist SKF 38393. Psychopharmacology 1994; 113:328–333.
   Google Scholar
• Terry P, Katz JL. Differential antagonism of the effects of dopamine DI-receptor agonist on feeding behavior in the rats. Psychopharmacology 1992; 109: 403–409.
   Google Scholar
• Goldstein JM. The new generation of antipsychotic drugs: how atypical are they? Int J Neuropsychopharma-cology 2000; 3(4):339–349.
   PubMed Web of Science ®Google Scholar
• Tecott LH, Sun LM, Akana SF, Strack AM, Lowenstein DH, Dallman MF, Julius D. Eating disorder and epilepsy in mice lacking 5-HT2c serotonin receptors. Nature 1995; 374(6522):542–546.
   Google Scholar
• Lawson WB, Byrd J, Reed D. Effects of neuroleptics on food intake. Soc Neurosci Abstract 1984; 303:68–72.
   Google Scholar
• Leibowitz SF, Rossakis C. Pharmacological character-ization of perifornical hypothalamus dopamine receptors mediating feeding inhibition in the rat. Brain Res 1979; 172:115–130.
   PubMedGoogle Scholar
• Campfield LA, Smith FJ, Guisez Y, Devos R, Burn P. Recombinant mouse OB protein: evidence for a peripheral signal linking adiposity and central neu-ral networks. Science 1995; 269(5223):546–549.
   Google Scholar
• Friedman JM, Halaas JL. Leptin and the regulation of body weight in mammals. Nature 1998; 22:263–770.
   Google Scholar
• Kraus T, Haack M, Schuld A, Hinze-Selch D, Kuhn M, Uhr M, Pollmacher T. Body weight and leptin plasma levels during treatment with antipsychotic drugs. Am J Psychiatry 1999; 156:321–324.
   Google Scholar
• Baptista T, Lacruz A, De Mendoza D, Mendoza JM, Silvera R, Angeles I, Mendoza MT, Hernandez L. Body weight gain after administration of antipsy-chotic drugs: correlation with leptin, insulin, and reproductive hormones. Pharmacopsychiatry 2000; 33:81–88.
   PubMed Web of Science ®Google Scholar
• Baptista T, Lacruz A, Mendoza S, Hernandez L. Endocrine effects of lithium carbonate in healthy post menopausal women: relationship with body weight regulation. Biol Psychiatry 2000; 24:1–16.
   Google Scholar
• Melkersson KI, Hulling AL, Brismar KE. Elevated levels of insulin, lepin, and blood lipids in olanzap-ine treated patients with schizophrenia or related pychoses. J Clin Psych 2000; 61(10):742–749.
   Google Scholar
• Ahren B, Larsson H, Wilhelmsson C, Nasman B, Olsson T. Regulation of circulating leptin in humans. Endocrine 1997; 7(1):1–8.
   Google Scholar
• Baptista T, Beaulieu S. Are leptin and cytokines involved in body weight gain during treatment with antipsychotic drugs? Can J Psychiatry 2002; 47: 742–749.
   PubMed Web of Science ®Google Scholar
• Yamaguchi T, Kamon J, Waki H, et al. The fat derived hormone adiponectin reverses insulin resis-tance associated with both lipoatrophy and obesity. Nature Medicine 2001; 7:941–946.
   Google Scholar
• Pollmacher T, Hinze-Selch D, Mullington J. Effects of clozapine on plasma cytokine and soluble cyto-kine receptor levels. J Clin Psychopharm 1996; 16(5):403–409.
   PubMed Web of Science ®Google Scholar
• Hinze-Selch D, Deuschle M, Weber B, Heuser I, Pollmacher T. Effect of co-administration of clozap-ine and fluvoxamine versus clozapine monotherapy on blood cell counts plasma levels of cytokines and bodyweight. Psychopharm 2000; 149:163–169.
   Google Scholar
• Argiles JM, Lopez-Soriano J, Busquets S, Lopez-Soriano FJ. Journey from cachexia to obesity by TNF. FASEB 1997; 11:743–751.
   PubMed Web of Science ®Google Scholar
• Auwerx J, Staels B. Leptin. Lancet 1998; 351:737–742.
   PubMed Web of Science ®Google Scholar
• Fontaine KR, Heo M, Harrigan EP, et al. Estimating the consequences of antipsychotic induced weight gain on health and mortality rate. Psych Res 2001; 101(3):277–288.
   PubMedGoogle Scholar
• Hauner H. The impact of pharmacotherapy on weight management in type 2 diabetes. In J Obes 1999; 23(Suppl 7):S12–S17.
   Google Scholar
• Winkelman JW. Schizophrenia obesity and obstructive sleep apnea. J Clin Psych 2001; 62:8–11.
   Google Scholar
• Rankinen T, Perusse L, Weisnagel SJ, Snyder EE, Chagon YC, Bouchard C. The human obesity gene map: the 2001 update. Obes Res 2002; 10(3): 196–243.
   Google Scholar
• Froguel P. Boutin P. Genetics of pathways regulating body weight in the development of obesity in humans. Exp Biol Med 2001; 226(11):991–996.
   Google Scholar
• Steppan CM, Lazar MA. Resistin and obesity-associated insulin resistance. Trends Endocrinol Metab 2002; 13(1):18–23.
   PubMed Web of Science ®Google Scholar
• Boelsterli UA, Bedoucha M. Toxicological conse-quences of altered peroxisome proliferator-activated receptor gamma (PPA Rgamma) expression in the liver: insights from models of obesity and type 2 diabetes. Biochem Pharmacol 2002; 63(1):1–10.
   Google Scholar
• Reinstein MJ, Sirotovskaya LA, Jones LE, Mohan S, Chasanov M. Effect of clozapine-quetiapine combina-tion therapy on weight and glycaemic control: prelim-inary findings. Clin Drug Inves 1999; 18:99–104.
   Google Scholar
• Jimerson DC, Lesem MD, Kaye WH, Hegg AP, Brewerton TD. Eating disorders and depression: is there a serotonin connection? Bio Psych 1991; 28(5):443–454.
   Google Scholar
• Grinspoon S, Gulick T, Askari H, et al. Serum leptin levels in women with anorexia nervosa. J Clin Endocrin Metab 1996; 81:3861–3863.
   PubMed Web of Science ®Google Scholar
• Kaye WH, Gwirtsman HE, George DT, Ebert MH. Altered serotonin activity in anorexia nervosa after long-term weight restoration: does elevated cerebro-spinal fluid 5-Hydroxyindoleacetic acid level correlate with rigid and obsessive behavior? Arch Gen Psych 1991; 48(6):556–562.
   Google Scholar
• Sullivan PF. Mortality in anorexia nervosa. Am J Psych 1995; 152:1073–1074.
   PubMed Web of Science ®Google Scholar
• Rigotti NA, Neer RM, Skates SJ, Herzog DB, Nussbaum SR. The clinical course of osteoporosis in anorexia nervosa. JAMA 1990; 265(9):1133–1138.
   Google Scholar
• Klibanski A, Biller BMK, Schoenfeld D, Herzog DB, Saxe V. The effects of estrogen administration on trabecular bone loss in young women with anorexia nervosa. J Clin Endocrin Met 1995; 80(3): 898–904 .
   Google Scholar
• Werneke U, Taylor D, Sanders TAB. Options for pharmacological management of obesity in patients treated with atypical antipsychotics. In Clinical Psychopharmacology 2002; 17:145–160.
   Google Scholar
• Wirth A. Long term weight loss with sibutramine: A randomized controlled trial. JAMA 2001; 286: 1331–1339.
   PubMed Web of Science ®Google Scholar
• Angelescu I, Klawe C, Benkert O. Orlistat in the treat-ment of psychopharmacologically induced weight gain. J Clin Psychopharm 2000; 20:716–717.
   Google Scholar
• Benazzi F. Depression induced by Orlistat (Xenecal). Can J Psychiatry 2000; 45:87.
   PubMed Web of Science ®Google Scholar
• Morrison JA, Cottingham EM, Barton BA. Metformin for weight loss in pediatric patients taking psychotro-pic drugs. Am J Psychiatry 2002; 159:655–657.
   Google Scholar
• Hutchison TA, Sharhan DR. DRUGDEX system. Greenwood Village, CO: Micromedex, Inc.; 2001.
   Google Scholar
• Levy E, Margolese HC, Chouinard G. Topiramate produced weight loss following olanzapine induced weight gain in schizophrenia. J Clin Psychiatry 2002; 63:1045.
   Google Scholar
• Ketter TA, Post RM, Theodore WH. Positive and neg-ative psychiatric effects on antiepileptic drugs in patients with seizure disorders. Neurology 1999; 53\(suppl 2):S53–S67.
   Google Scholar
• Dursun SM, Devarajan S. Clozapine weight gain, plus topiramate weight loss. Can J Psych 2000; 45(2): 198.
   Google Scholar
• Correa N, Opler LA, Kay SR, Birmaher B. Amanta-dine in the treatment of neuroendorine side effects of neuroleptics. J Clin Psychopharm 1987; 7:91–95.
   PubMed Web of Science ®Google Scholar
• Floris M, Lejeunne J, Deberdt W. Effect of amanta-dine on weight gain during olanzapine treatment. Eur J Neuropsychopharmacology 2002; 11:181–182.
   Google Scholar
• Wilcox J, Tsuang J. Psychological effects of amanta-dine on psychotic subjects. Neuropsychobiology 1990; 23:144–146.
   PubMed Web of Science ®Google Scholar
• Sachetti E, Guarner L, Bravi D. H(2) antagonist niza-tidine may control olanzapine-associated weight gain in schizophrenic patients. Biol Psychiatry 2000; 48:167–168.
   Google Scholar
• Stoa-Birketvedt G, Waldum HL, Vonen B, Florholmen J. Effect of cimetidine on basal and postprandial plasma concentrations of cholecystokinin and gastrin in humans. Acta Physiol Scand 1997; 159(4):321–325.
   Google Scholar
• Stoa-Birketvedt G, Paus PN, Gnass R. Cimetidne reduces weight gain and improves metabolic control in overweight patients with type 2 diabetes. J Obes Relat Metab Disord 1998; 22:1041–1045.
   Google Scholar